[Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Keisuke
K
Miyazawa
D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D003841:Deoxycytidine / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D018390:Gene Targeting; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000503:physiopathology*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D007502:Iron Chelating Agents; D014409:Tumor Necrosis Factor-alpha; D003841:Deoxycytidine; D013792:Thalidomide; D000077209:Decitabine; D000077269:Lenalidomide; D001374:Azacitidine